Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 1/2013

01-01-2013 | Original article

A knockdown of Maml1 that results in melanoma cell senescence promotes an innate and adaptive immune response

Authors: Shijun Kang, Jianmin Xie, Jingxia Miao, Rong Li, Wangjun Liao, Rongcheng Luo

Published in: Cancer Immunology, Immunotherapy | Issue 1/2013

Login to get access

Abstract

Maml1 is emerging as a coactivator of many signaling pathways, including the Notch and Wnt pathways. Targeting Maml1 in melanoma cells efficiently knocks down the downstream transcriptional repressors Hey1 and Hes1, resulting in melanoma cell senescence, cellular differentiation, and increased melanin production. Significantly, higher IFNβ and chemokine gene transcripts have been observed, together with increased STAT1 and decreased STAT3 and NF-κB signaling activities. Although decreased cell proliferation contributes to slower tumor growth in vivo, the depletion of NK and CD8+ T cells in an shMaml1-B16 tumor carrier mouse leads to more rapid tumor growth than that observed in control shC002-B16 tumors. This result demonstrates that the knockdown of Maml1 transcription and function contributes to increased immune surveillance. The knockdown of Maml1 transcription in the human melanoma cell line M537 also results in senescence, IFNβ upregulation, increased chemokine gene expression, and greater NK and CD8+ T cell migration in a transwell system. This study demonstrated that targeting Maml1-induced tumor cell senescence and differentiation may alter the tumor microenvironment and cytokine and chemokine profiles and may also promote innate and adaptive immune cell infiltration and function.
Literature
1.
go back to reference Takebe N, Harris PJ, Warren RQ, Ivy SP (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8:97–106PubMedCrossRef Takebe N, Harris PJ, Warren RQ, Ivy SP (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8:97–106PubMedCrossRef
2.
go back to reference Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB (2009) Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8:806–823PubMedCrossRef Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB (2009) Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8:806–823PubMedCrossRef
3.
go back to reference Crea F, Duhagon MA, Farrar WL, Danesi R (2011) Pharmacogenomics and cancer stem cells: a changing landscape? Trends Pharmacol Sci 32:487–494PubMedCrossRef Crea F, Duhagon MA, Farrar WL, Danesi R (2011) Pharmacogenomics and cancer stem cells: a changing landscape? Trends Pharmacol Sci 32:487–494PubMedCrossRef
4.
go back to reference Radtke F, Raj K (2003) The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 3:756–767PubMedCrossRef Radtke F, Raj K (2003) The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 3:756–767PubMedCrossRef
5.
go back to reference Hansson EM, Lendahl U, Chapman G (2004) Notch signaling in development and disease. Semin Cancer Biol 14:320–328PubMedCrossRef Hansson EM, Lendahl U, Chapman G (2004) Notch signaling in development and disease. Semin Cancer Biol 14:320–328PubMedCrossRef
6.
go back to reference Nickoloff BJ, Osborne BA, Miele L (2003) Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 22:6598–6608PubMedCrossRef Nickoloff BJ, Osborne BA, Miele L (2003) Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 22:6598–6608PubMedCrossRef
7.
go back to reference Kang S, Yang C, Luo R (2008) Induction of CCL2 by siMAML1 through upregulation of TweakR in melanoma cells. Biochem Biophys Res Commun 372:629–633PubMedCrossRef Kang S, Yang C, Luo R (2008) Induction of CCL2 by siMAML1 through upregulation of TweakR in melanoma cells. Biochem Biophys Res Commun 372:629–633PubMedCrossRef
8.
go back to reference Kopan R, Ilagan MX (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137:216–233PubMedCrossRef Kopan R, Ilagan MX (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137:216–233PubMedCrossRef
9.
go back to reference Alves-Guerra MC, Ronchini C, Capobianco AJ (2007) Mastermind-like 1 Is a specific coactivator of beta-catenin transcription activation and is essential for colon carcinoma cell survival. Cancer Res 67:8690–8698PubMedCrossRef Alves-Guerra MC, Ronchini C, Capobianco AJ (2007) Mastermind-like 1 Is a specific coactivator of beta-catenin transcription activation and is essential for colon carcinoma cell survival. Cancer Res 67:8690–8698PubMedCrossRef
10.
go back to reference Shimizu T, Kagawa T, Inoue T, Nonaka A, Takada S, Aburatani H, Taga T (2008) Stabilized beta-catenin functions through TCF/LEF proteins and the Notch/RBP-Jkappa complex to promote proliferation and suppress differentiation of neural precursor cells. Mol Cell Biol 28:7427–7441PubMedCrossRef Shimizu T, Kagawa T, Inoue T, Nonaka A, Takada S, Aburatani H, Taga T (2008) Stabilized beta-catenin functions through TCF/LEF proteins and the Notch/RBP-Jkappa complex to promote proliferation and suppress differentiation of neural precursor cells. Mol Cell Biol 28:7427–7441PubMedCrossRef
11.
go back to reference Ingram WJ, McCue KI, Tran TH, Hallahan AR, Wainwright BJ (2008) Sonic Hedgehog regulates Hes1 through a novel mechanism that is independent of canonical Notch pathway signalling. Oncogene 27:1489–1500PubMedCrossRef Ingram WJ, McCue KI, Tran TH, Hallahan AR, Wainwright BJ (2008) Sonic Hedgehog regulates Hes1 through a novel mechanism that is independent of canonical Notch pathway signalling. Oncogene 27:1489–1500PubMedCrossRef
12.
go back to reference Wall DS, Mears AJ, McNeill B, Mazerolle C, Thurig S, Wang Y, Kageyama R, Wallace VA (2009) Progenitor cell proliferation in the retina is dependent on Notch-independent Sonic hedgehog/Hes1 activity. J Cell Biol 184:101–112PubMedCrossRef Wall DS, Mears AJ, McNeill B, Mazerolle C, Thurig S, Wang Y, Kageyama R, Wallace VA (2009) Progenitor cell proliferation in the retina is dependent on Notch-independent Sonic hedgehog/Hes1 activity. J Cell Biol 184:101–112PubMedCrossRef
13.
go back to reference Hatton BA, Villavicencio EH, Pritchard J, LeBlanc M, Hansen S, Ulrich M, Ditzler S, Pullar B, Stroud MR, Olson JM (2010) Notch signaling is not essential in sonic hedgehog-activated medulloblastoma. Oncogene 29:3865–3872PubMedCrossRef Hatton BA, Villavicencio EH, Pritchard J, LeBlanc M, Hansen S, Ulrich M, Ditzler S, Pullar B, Stroud MR, Olson JM (2010) Notch signaling is not essential in sonic hedgehog-activated medulloblastoma. Oncogene 29:3865–3872PubMedCrossRef
14.
go back to reference Sang L, Roberts JM, Coller HA (2010) Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells. Trends Mol Med 16:17–26 Sang L, Roberts JM, Coller HA (2010) Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells. Trends Mol Med 16:17–26
15.
go back to reference Schreck KC, Taylor P, Marchionni L, Gopalakrishnan V, Bar EE, Gaiano N, Eberhart CG (2010) The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin Cancer Res 16:6060–6070PubMedCrossRef Schreck KC, Taylor P, Marchionni L, Gopalakrishnan V, Bar EE, Gaiano N, Eberhart CG (2010) The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin Cancer Res 16:6060–6070PubMedCrossRef
16.
go back to reference Sang L, Coller HA (2009) Fear of commitment: Hes1 protects quiescent fibroblasts from irreversible cellular fates. Cell Cycle 8:2161–2167PubMedCrossRef Sang L, Coller HA (2009) Fear of commitment: Hes1 protects quiescent fibroblasts from irreversible cellular fates. Cell Cycle 8:2161–2167PubMedCrossRef
17.
go back to reference Sang L, Coller HA, Roberts JM (2008) Control of the reversibility of cellular quiescence by the transcriptional repressor HES1. Science 321:1095–1100PubMedCrossRef Sang L, Coller HA, Roberts JM (2008) Control of the reversibility of cellular quiescence by the transcriptional repressor HES1. Science 321:1095–1100PubMedCrossRef
18.
go back to reference Wu L, Kobayashi K, Sun T, Gao P, Liu J, Nakamura M, Weisberg E, Mukhopadhyay NK, Griffin JD (2004) Cloning and functional characterization of the murine mastermind-like 1 (Maml1) gene. Gene 328:153–165PubMedCrossRef Wu L, Kobayashi K, Sun T, Gao P, Liu J, Nakamura M, Weisberg E, Mukhopadhyay NK, Griffin JD (2004) Cloning and functional characterization of the murine mastermind-like 1 (Maml1) gene. Gene 328:153–165PubMedCrossRef
19.
go back to reference Jin B, Shen H, Lin S, Li JL, Chen Z, Griffin JD, Wu L (2010) The mastermind-like 1 (MAML1) co-activator regulates constitutive NF-kappaB signaling and cell survival. J Biol Chem 285:14356–14365 Jin B, Shen H, Lin S, Li JL, Chen Z, Griffin JD, Wu L (2010) The mastermind-like 1 (MAML1) co-activator regulates constitutive NF-kappaB signaling and cell survival. J Biol Chem 285:14356–14365
21.
go back to reference Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, Kung AL, Gilliland DG, Verdine GL, Bradner JE (2009) Direct inhibition of the NOTCH transcription factor complex. Nature 462:182–188PubMedCrossRef Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, Kung AL, Gilliland DG, Verdine GL, Bradner JE (2009) Direct inhibition of the NOTCH transcription factor complex. Nature 462:182–188PubMedCrossRef
22.
go back to reference Bartlett DW, Davis ME (2006) Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 34:322–333PubMedCrossRef Bartlett DW, Davis ME (2006) Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 34:322–333PubMedCrossRef
23.
go back to reference Kang S, Xie J, Ma S, Liao W, Zhang J, Luo R (2010) Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets. Immunobiology 215:153–162 Kang S, Xie J, Ma S, Liao W, Zhang J, Luo R (2010) Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets. Immunobiology 215:153–162
24.
go back to reference Hiroi M, Ohmori Y (2003) Constitutive nuclear factor kappaB activity is required to elicit interferon-gamma-induced expression of chemokine CXC ligand 9 (CXCL9) and CXCL10 in human tumour cell lines. Biochem J 376:393–402PubMedCrossRef Hiroi M, Ohmori Y (2003) Constitutive nuclear factor kappaB activity is required to elicit interferon-gamma-induced expression of chemokine CXC ligand 9 (CXCL9) and CXCL10 in human tumour cell lines. Biochem J 376:393–402PubMedCrossRef
25.
go back to reference Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, Vago L, Nebuloni M, Mantovani A, Sica A (2006) A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107:2112–2122PubMedCrossRef Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, Vago L, Nebuloni M, Mantovani A, Sica A (2006) A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107:2112–2122PubMedCrossRef
26.
go back to reference Riccio O, van Gijn ME, Bezdek AC, Pellegrinet L, van Es JH, Zimber-Strobl U, Strobl LJ, Honjo T, Clevers H, Radtke F (2008) Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep 9:377–383PubMedCrossRef Riccio O, van Gijn ME, Bezdek AC, Pellegrinet L, van Es JH, Zimber-Strobl U, Strobl LJ, Honjo T, Clevers H, Radtke F (2008) Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep 9:377–383PubMedCrossRef
27.
go back to reference Kavanagh E, Joseph B (2011) The hallmarks of CDKN1C (p57, KIP2) in cancer. Biochim Biophys Acta 1816:50–56 Kavanagh E, Joseph B (2011) The hallmarks of CDKN1C (p57, KIP2) in cancer. Biochim Biophys Acta 1816:50–56
28.
go back to reference Jin B, Shen H, Lin S, Li JL, Chen Z, Griffin JD, Wu L (2010) The mastermind-like 1 (MAML1) co-activator regulates constitutive NF-kappaB signaling and cell survival. J Biol Chem 285:14356–14365PubMedCrossRef Jin B, Shen H, Lin S, Li JL, Chen Z, Griffin JD, Wu L (2010) The mastermind-like 1 (MAML1) co-activator regulates constitutive NF-kappaB signaling and cell survival. J Biol Chem 285:14356–14365PubMedCrossRef
29.
go back to reference Cao Q, Kaur C, Wu CY, Lu J, Ling EA (2011) Nuclear factor-kappa beta regulates Notch signaling in production of proinflammatory cytokines and nitric oxide in murine BV-2 microglial cells. Neuroscience 192:140–154 Cao Q, Kaur C, Wu CY, Lu J, Ling EA (2011) Nuclear factor-kappa beta regulates Notch signaling in production of proinflammatory cytokines and nitric oxide in murine BV-2 microglial cells. Neuroscience 192:140–154
30.
go back to reference Bhoopathi P, Chetty C, Dontula R, Gujrati M, Dinh DH, Rao JS, Lakka SS (2011) SPARC stimulates neuronal differentiation of medulloblastoma cells via the Notch1/STAT3 pathway. Cancer Res 71:4908–4919 Bhoopathi P, Chetty C, Dontula R, Gujrati M, Dinh DH, Rao JS, Lakka SS (2011) SPARC stimulates neuronal differentiation of medulloblastoma cells via the Notch1/STAT3 pathway. Cancer Res 71:4908–4919
31.
go back to reference Lee JH, Suk J, Park J, Kim SB, Kwak SS, Kim JW, Lee CH, Byun B, Ahn JK, Joe CO (2009) Notch signal activates hypoxia pathway through HES1-dependent SRC/signal transducers and activators of transcription 3 pathway. Mol Cancer Res 7:1663–1671PubMedCrossRef Lee JH, Suk J, Park J, Kim SB, Kwak SS, Kim JW, Lee CH, Byun B, Ahn JK, Joe CO (2009) Notch signal activates hypoxia pathway through HES1-dependent SRC/signal transducers and activators of transcription 3 pathway. Mol Cancer Res 7:1663–1671PubMedCrossRef
32.
go back to reference Ma J, Meng Y, Kwiatkowski DJ, Chen X, Peng H, Sun Q, Zha X, Wang F, Wang Y, Jing Y, Zhang S, Chen R, Wang L, Wu E, Cai G, Malinowska-Kolodziej I, Liao Q, Liu Y, Zhao Y, Xu K, Dai J, Han J, Wu L, Zhao RC, Shen H, Zhang H (2010) Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Invest 120:103–114 Ma J, Meng Y, Kwiatkowski DJ, Chen X, Peng H, Sun Q, Zha X, Wang F, Wang Y, Jing Y, Zhang S, Chen R, Wang L, Wu E, Cai G, Malinowska-Kolodziej I, Liao Q, Liu Y, Zhao Y, Xu K, Dai J, Han J, Wu L, Zhao RC, Shen H, Zhang H (2010) Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Invest 120:103–114
33.
go back to reference Lee H, Deng J, Xin H, Liu Y, Pardoll D, Yu H (2011) A requirement of STAT3 DNA binding precludes Th-1 immunostimulatory gene expression by NF-kappaB in tumors. Cancer Res 71:3772–3780 Lee H, Deng J, Xin H, Liu Y, Pardoll D, Yu H (2011) A requirement of STAT3 DNA binding precludes Th-1 immunostimulatory gene expression by NF-kappaB in tumors. Cancer Res 71:3772–3780
34.
go back to reference Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM, Yu H (2009) Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15:283–293PubMedCrossRef Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM, Yu H (2009) Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15:283–293PubMedCrossRef
35.
go back to reference Lee H, Pal SK, Reckamp K, Figlin RA, Yu H (2011) STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol 344:41–59 Lee H, Pal SK, Reckamp K, Figlin RA, Yu H (2011) STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol 344:41–59
36.
go back to reference Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798–809PubMedCrossRef Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798–809PubMedCrossRef
37.
go back to reference Regis G, Pensa S, Boselli D, Novelli F, Poli V (2008) Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. Semin Cell Dev Biol 19:351–359PubMedCrossRef Regis G, Pensa S, Boselli D, Novelli F, Poli V (2008) Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. Semin Cell Dev Biol 19:351–359PubMedCrossRef
38.
go back to reference Pinho AV, Rooman I, Reichert M, De Medts N, Bouwens L, Rustgi AK, Real FX (2011) Adult pancreatic acinar cells dedifferentiate to an embryonic progenitor phenotype with concomitant activation of a senescence programme that is present in chronic pancreatitis. Gut 60:958–966PubMedCrossRef Pinho AV, Rooman I, Reichert M, De Medts N, Bouwens L, Rustgi AK, Real FX (2011) Adult pancreatic acinar cells dedifferentiate to an embryonic progenitor phenotype with concomitant activation of a senescence programme that is present in chronic pancreatitis. Gut 60:958–966PubMedCrossRef
39.
go back to reference Lleonart ME, Artero-Castro A, Kondoh H (2009) Senescence induction; a possible cancer therapy. Mol Cancer 8:3PubMedCrossRef Lleonart ME, Artero-Castro A, Kondoh H (2009) Senescence induction; a possible cancer therapy. Mol Cancer 8:3PubMedCrossRef
40.
go back to reference Roninson IB (2003) Tumor cell senescence in cancer treatment. Cancer Res 63:2705–2715PubMed Roninson IB (2003) Tumor cell senescence in cancer treatment. Cancer Res 63:2705–2715PubMed
41.
go back to reference Schmitt CA (2007) Cellular senescence and cancer treatment. Biochim Biophys Acta 1775:5–20PubMed Schmitt CA (2007) Cellular senescence and cancer treatment. Biochim Biophys Acta 1775:5–20PubMed
42.
go back to reference Kahlem P, Dorken B, Schmitt CA (2004) Cellular senescence in cancer treatment: friend or foe? J Clin Invest 113:169–174PubMed Kahlem P, Dorken B, Schmitt CA (2004) Cellular senescence in cancer treatment: friend or foe? J Clin Invest 113:169–174PubMed
43.
go back to reference Freund A, Orjalo AV, Desprez PY, Campisi J (2010) Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med 16:238–246PubMedCrossRef Freund A, Orjalo AV, Desprez PY, Campisi J (2010) Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med 16:238–246PubMedCrossRef
44.
go back to reference Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445:656–660PubMedCrossRef Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445:656–660PubMedCrossRef
45.
go back to reference Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, Fan AC, Yang Q, Braunstein L, Crosby E, Ryeom S, Felsher DW (2010) CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18:485–498PubMedCrossRef Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, Fan AC, Yang Q, Braunstein L, Crosby E, Ryeom S, Felsher DW (2010) CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18:485–498PubMedCrossRef
Metadata
Title
A knockdown of Maml1 that results in melanoma cell senescence promotes an innate and adaptive immune response
Authors
Shijun Kang
Jianmin Xie
Jingxia Miao
Rong Li
Wangjun Liao
Rongcheng Luo
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 1/2013
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-012-1318-1

Other articles of this Issue 1/2013

Cancer Immunology, Immunotherapy 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine